Remeditex was formed to invest in high quality, innovative, early stage projects that are judged to have commercialization potential. The goal is to help investigators establish the commercial viability of their research making it attractive to traditional investors.
|BiO2 Medical||9/12||Series C||$12M||2|
|Miragen Therapeutics||4/12||Series B||$20M||5|
|Bellicum Pharmaceuticals||3/12||Series B||$20M||4|
|Peloton Therapeutics||7/11||Series A||$18M||2|